T01: Harnessing hepatic tolerance mechanisms for antigen-specific treatment of autoimmune and allergic diseases

T01_Carambia_Heeren_Herkel_FP3

Principal investigators:

Prof. Dr. Johannes Herkel
I. Medizinische Klinik und Poliklinik
Universitätsklinikum Hamburg-Eppendorf
Martinistr.52
20246 Hamburg
Tel.: +49-40-7410-59736
E-Mail: jherkel@uke.uni-hamburg.de

Dr. Antonella Carambia
I. Medizinische Klinik und Poliklinik
Universitätsklinikum Hamburg-Eppendorf
Martinistr.52
20246 Hamburg
Tel.: +49-40-7410-52495
E-Mail: a.carambia@uke.uni-hamburg.de

Prof. Dr. Jörg Heeren
Institut für Biochemie und Molekulare Zellbiologie,
Universitätsklinikum Hamburg-Eppendorf
Martinistr. 52
20246 Hamburg
Tel.: +49-40-7410-54745
E-Mail: heeren@uke.uni-hamburg.de

Application partner:

Topas Therapeutics GmbH
Dr. Johannes Pohlner
Falkenried 88, Haus A,
20251 Hamburg
Tel.: +49-40-47196-321
E-Mail: pohlner@topas-therapeutics.com

T01 in 60 SecondsVideoarchiv

online seit 03.07.2019

Project description

The lack of causative treatments for autoimmune diseases that specifically suppress only the disease-relevant immune responses while leaving desired immune responses unaffected is a yet unmet major biomedical challenge.

We have shown that the selective delivery of disease-relevant peptides to liver sinusoidal endothelial cells (LSECs) using LSEC-targeting nanocarriers can provide specific control of undesired immune reactions. Proof-of-concept was obtained in CD4+ T cell-driven animal models of multiple sclerosis (MS), demonstrating safety and exceptional efficacy both in preventing disease flares and in alleviating established disease.

Here, we explore the applicability of this treatment concept in a variety of other autoimmune diseases. The project marks an essential step towards the clinical application of our treatment approach, as it seek to obtain proof-of-concept in relevant preclinical models and facilitates the development of a therapeutic platform potentially applicable to a wide range of autoimmune and allergic diseases.